Targeting Mitochondrial Dysfunction for the Prevention and Treatment of Non-Alcoholic Fatty Liver Disease

Non-alcoholic fatty liver disease (NAFLD) has emerged as the most prevalent chronic liver disorder worldwide, with its prevalence closely linked to metabolic comorbidities. Mitochondrial dysfunction, a central mechanism underlying metabolic dysregulation, is recognized as a critical driver of NAFLD pathogenesis. This review systematically delineates the molecular mechanisms of mitochondrial dysfunction in NAFLD, encompassing multidimensional networks such as mitochondrial dynamics imbalance, oxidative stress, aberrant metabolic signaling, and inter-organelle crosstalk. Furthermore, we propose novel mitochondrial-targeted therapeutic strategies for NAFLD, including restoration of energy metabolism and mitigation of oxidative damage through antioxidant interventions, modulation of mitochondrial dynamics, and activation of autophagy. Finally, we summarize current research limitations and future directions in targeting mitochondrial dysfunction. By integrating existing evidence, this review establishes a robust theoretical framework for mitochondrial-targeted therapies in NAFLD, offering innovative clinical approaches and a transformative paradigm for addressing the global burden of metabolic liver diseases.

• Publication year

  2025

• Venue

  Natural Product Communications

• Publication date

  2025-11-01

• Fields of study

  Not labeled

• Identifiers
  DOI 10.1177/1934578X251403971
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Analysis of the Mitochondrial Dynamics in NAFLD: Drp1 as a Marker of Inflammation and Fibrosis

  2025cited by this paper
• Author Correction: Mitochondrion-specific dendritic lipopeptide liposomes for targeted sub-cellular delivery

  2025cited by this paper
• Advancing cancer therapy: Nanomaterial-based encapsulation strategies for enhanced delivery and efficacy of curcumin

  2025cited by this paper
• Adaptation under constant light or dark: a challenge to the pineal

  2025cited by this paper
• Mitochondrial Transplantation/Transfer: Promising Therapeutic Strategies for Spinal Cord Injury

  2025cited by this paper
• Circadian clockwork controls the balance between mitochondrial turnover and dynamics: What is life … without time marking?

  2025cited by this paper
• The role of clock control of DRP1 activity involved in postoperative cognitive dysfunction.

  2025cited by this paper
• N‐lactoyl amino acids are potential biomarkers for insulin resistance and diabetic complications

  2025cited by this paper
• Novel blood and tissue-based mitochondrial D-loop mutations detected in an Iranian NAFLD patient cohort.

  2024cited by this paper
• Mitochondrial dynamics, quality control and mtDNA in Alcohol-associated liver disease and liver cancer.

  2024cited by this paper
• Machine learning deciphers the significance of mitochondrial regulators on the diagnosis and subtype classification in non-alcoholic fatty liver disease

  2024cited by this paper
• Chinese medicine in the treatment of non-alcoholic fatty liver disease based on network pharmacology: a review

  2024cited by this paper
• The gut-liver axis in fatty liver disease: role played by natural products.

  2024cited by this paper
• Hydrogen sulfide supplementation as a potential treatment for primary mitochondrial diseases.

  2024cited by this paper
• Emerging role of ferroptosis in metabolic dysfunction-associated steatotic liver disease: revisiting hepatic lipid peroxidation

  2024cited by this paper
• Peripheral amyloid-β clearance mediates cognitive impairment in non-alcoholic fatty liver disease

  2024cited by this paper
• Evolving liver disease insights from NAFLD to MASLD.

  2024cited by this paper
• Cross talk between the liver microbiome and epigenome in patients with metabolic dysfunction-associated steatotic liver disease

  2024cited by this paper
• GLP-1/GLP-1RAs: New Options for the Drug Treatment of NAFLD.

  2024cited by this paper
• Revitalizing Ancient Mitochondria with Nano‐Strategies: Mitochondria‐Remedying Nanodrugs Concentrate on Disease Control

  2024cited by this paper
• Lactobacillus acidophilus suppresses non-alcoholic fatty liver disease-associated hepatocellular carcinoma through producing valeric acid

  2024cited by this paper
• Therapeutic management of metabolic dysfunction associated steatotic liver disease

  2024cited by this paper
• Application and mechanism of Chinese herb medicine in the treatment of non-alcoholic fatty liver disease

  2024cited by this paper
• Hesperitin prevents non-alcoholic steatohepatitis by modulating mitochondrial dynamics and mitophagy via the AMPKα-Drp1/PINK1-Parkin signaling pathway.

  2024cited by this paper
• The Potential Role of Mitochondria in the Microbiota-Gut-Brain Axis: Implications for Brain Health.

  2024cited by this paper
• Targeting mitochondrial homeostasis in the treatment of non-alcoholic fatty liver disease: a review

  2024cited by this paper
• Single nucleus RNA-sequencing integrated into risk variant colocalization discovers 17 cell-type-specific abdominal obesity genes for metabolic dysfunction-associated steatotic liver disease

  2024cited by this paper
• TFAM is an autophagy receptor that limits inflammation by binding to cytoplasmic mitochondrial DNA

  2024cited by this paper
• FGF21 Agonists: An Emerging Therapeutic for Metabolic Dysfunction-Associated Steatohepatitis and Beyond.

  2024cited by this paper
• Chaperonin counteracts diet-induced non-alcoholic fatty liver disease by aiding sirtuin 3 in the control of fatty acid oxidation

  2023cited by this paper
• Intranasal Delivery of Mitochondria Attenuates Brain Injury by AMPK and SIRT1/PGC-1α Pathways in a Murine Model of Photothrombotic Stroke

  2023cited by this paper
• 5‐Aza‐2′‐deoxycytidine‐mediated DNA hypomethylation with and without concurrent insulin resistance suppresses myotube mitochondrial capacity

  2023cited by this paper
• Therapeutic efficacy of mitochondria-targeted esculetin in the improvement of NAFLD-NASH via modulating AMPK-SIRT1 axis.

  2023cited by this paper
• Nano-drug delivery system targeting tumor microenvironment: A prospective strategy for melanoma treatment.

  2023cited by this paper
• A high fat, high sugar diet induces hepatic Peroxisome proliferator-activated receptor gamma coactivator 1-alpha promoter hypermethylation in male Wistar rats.

  2023cited by this paper
• Mitochondrial metabolic dysfunction and non-alcoholic fatty liver disease: new insights from pathogenic mechanisms to clinically targeted therapy

  2023cited by this paper
• Global prevalence of non-alcoholic fatty liver disease in type 2 diabetes mellitus: an updated systematic review and meta-analysis

  2023cited by this paper
• The emerging significance of mitochondrial targeted strategies in NAFLD treatment.

  2023cited by this paper
• Chronic mitochondria antioxidant treatment in older adults alters the circulating milieu to improve endothelial cell function and mitochondrial oxidative stress.

  2023cited by this paper
• Low-Dose Acetylsalicylic Acid and Mitochondria-Targeted Antioxidant Mitoquinone Attenuate Non-Alcoholic Steatohepatitis in Mice

  2023cited by this paper
• Alterations in Cytoskeleton and Mitochondria in the Development and Reversal of Steatosis in Human Hepatocytes

  2023cited by this paper
• Effects of Curcumin on Oxidative Stress and Ferroptosis in Acute Ammonia Stress-Induced Liver Injury in Gibel Carp (Carassius gibelio)

  2023cited by this paper
• Exercise activates Sirt1-mediated Drp1 acetylation and inhibits hepatocyte apoptosis to improve nonalcoholic fatty liver disease

  2023cited by this paper
• Chemical inhibition of mitochondrial fission via targeting the DRP1-receptor interaction.

  2023cited by this paper
• Hepatic Mitochondria-Gut Microbiota Interactions in Metabolism-Associated Fatty Liver Disease

  2023cited by this paper
• Efficacy of 3 months of additional pioglitazone treatment in type 2 diabetes patients with alcoholic fatty liver disease

  2023cited by this paper
• The impact of oxidative stress-induced mitochondrial dysfunction on diabetic microvascular complications

  2023cited by this paper
• Time to Change: A Systems Pharmacology Approach to Disentangle Mechanisms of Drug-Induced Mitochondrial Toxicity

  2023cited by this paper
• Circadian Control of Mitochondria in Reactive Oxygen Species Homeostasis

  2022cited by this paper
• ALKBH5 attenuates mitochondrial fission and ameliorates liver fibrosis by reducing Drp1 methylation.

  2022cited by this paper
• Current Advancements Related to Phytobioactive Compounds Based Liposomal Delivery for Neurodegenerative Diseases.

  2022cited by this paper
• Peripheral blood mononuclear cell mitochondrial copy number and adenosine triphosphate inhibition test in NAFLD

  2022cited by this paper
• Mitochondrial alterations in fatty liver diseases.

  2022cited by this paper
• The beneficial role of SIRT1 in preventive or therapeutic options of Neurodegenerative Diseases.

  2022cited by this paper
• The mitochondrial fission protein Drp1 in liver is required to mitigate NASH and prevents the activation of the mitochondrial ISR

  2022cited by this paper
• Environmental Chemical Exposures and Mitochondrial Dysfunction: a Review of Recent Literature

  2022cited by this paper
• Hepatocyte Mitochondrial Dynamics and Bioenergetics in Obesity-Related Non-Alcoholic Fatty Liver Disease

  2022cited by this paper
• Drug therapy for osteoporosis in older adults.

  2022cited by this paper
• Melatonin Attenuates Ischemia/Reperfusion-Induced Oxidative Stress by Activating Mitochondrial Fusion in Cardiomyocytes

  2022cited by this paper
• Renal mitochondrial injury in the pathogenesis of CKD: mtDNA and mitomiRs.

  2022cited by this paper
• Mitochondria homeostasis: Biology and involvement in hepatic steatosis to NASH

  2022cited by this paper
• N-acetyl L-cysteine ameliorates mitochondrial dysfunction in ischemia/reperfusion injury via attenuating Drp-1 mediated mitochondrial autophagy.

  2022cited by this paper
• Baicalein Enhances the Effect of Acarbose on the Improvement of Nonalcoholic Fatty Liver Disease Associated with Prediabetes via the Inhibition of De Novo Lipogenesis.

  2021cited by this paper
• Hydralazine protects the heart against acute ischaemia/reperfusion injury by inhibiting Drp1-mediated mitochondrial fission

  2021cited by this paper
• Mitochondrial dynamics and nonalcoholic fatty liver disease (NAFLD): new perspectives for a fairy-tale ending?

  2021cited by this paper
• Protein liposomes-mediated targeted acetylcholinesterase gene delivery for effective liver cancer therapy

  2021cited by this paper
• Mitophagy: An Emerging Target in Ocular Pathology

  2021cited by this paper
• Dysregulation of autophagy acts as a pathogenic mechanism of non-alcoholic fatty liver disease (NAFLD) induced by common environmental pollutants.

  2021cited by this paper
• Mitochondria antioxidant protection against cardiovascular dysfunction programmed by early-onset gestational hypoxia

  2021cited by this paper
• Protocols for Mitochondria as the Target of Pharmacological Therapy in the Context of Nonalcoholic Fatty Liver Disease (NAFLD).

  2021cited by this paper
• Mitochondrial Quality Control in Cerebral Ischemia–Reperfusion Injury

  2021cited by this paper
• Mitochondrial Dysfunction in Vascular Wall Cells and Its Role in Atherosclerosis

  2021cited by this paper
• Rescuing mitochondria in traumatic brain injury and intracerebral hemorrhages - A potential therapeutic approach.

  2021cited by this paper
• The Role and Mechanism of Oxidative Stress and Nuclear Receptors in the Development of NAFLD

  2021cited by this paper
• The Arabidopsis Circadian Clock and Metabolic Energy: A Question of Time

  2021cited by this paper
• Mitochondrial Dysfunction and Diabetic Nephropathy: Nontraditional Therapeutic Opportunities

  2021cited by this paper
• Mitochondrial Targeting Therapeutics: Promising Role of Natural Products in Non-alcoholic Fatty Liver Disease

  2021cited by this paper
• Mitochondrial dysfunction as a mechanistic biomarker in patients with Non-Alcoholic fatty liver disease (NAFLD).

  2020cited by this paper
• Mitochondrial oxidative function in NAFLD: Friend or foe?

  2020cited by this paper
• The combination of T-2 toxin and acrylamide synergistically induces hepatotoxicity and nephrotoxicity via the activation of oxidative stress and the mitochondrial pathway.

  2020cited by this paper
• Delivery of a mitochondria‐targeted antioxidant from biocompatible, polymeric nanofibrous scaffolds

  2020cited by this paper
• Angiotensin‐(1‐7), the product of ACE2 ameliorates NAFLD by acting through its receptor Mas to regulate hepatic mitochondrial function and glycolipid metabolism

  2020cited by this paper
• PGC-1α-mediated regulation of mitochondrial function and physiological implications.

  2020cited by this paper
• Sepsis-Induced Myocardial Dysfunction (SIMD): the Pathophysiological Mechanisms and Therapeutic Strategies Targeting Mitochondria

  2020cited by this paper
• Identify Molecular Mechanisms of Jiangzhi Decoction on Nonalcoholic Fatty Liver Disease by Network Pharmacology Analysis and Experimental Validation

  2020cited by this paper
• Bnip3 in mitophagy: novel insights and potential therapeutic target for diseases of secondary mitochondrial dysfunction.

  2020cited by this paper
• The Effects of RKI-1447 in a Mouse Model of Nonalcoholic Fatty Liver Disease Induced by a High-Fat Diet and in HepG2 Human Hepatocellular Carcinoma Cells Treated with Oleic Acid

  2020cited by this paper
• Plasma Krebs Cycle Intermediates in Nonalcoholic Fatty Liver Disease

  2020cited by this paper
• Mitochondrial oxidative phosphorylation is impaired in TALLYHO mice, a new obesity and type 2 diabetes animal model.

  2019cited by this paper
• Role of Vitamin E for Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes: A Randomized Controlled Trial

  2019cited by this paper
• Role of Cardiolipin in Mitochondrial Function and Dynamics in Health and Disease: Molecular and Pharmacological Aspects

  2019cited by this paper
• Mst1 inhibition attenuates non-alcoholic fatty liver disease via reversing Parkin-related mitophagy

  2019cited by this paper
• Plant Sterol Ester of α-Linolenic Acid Attenuates Nonalcoholic Fatty Liver Disease by Rescuing the Adaption to Endoplasmic Reticulum Stress and Enhancing Mitochondrial Biogenesis

  2019cited by this paper
• Mitochondrially-targeted treatment strategies.

  2019cited by this paper
• Electrophilic nitro-oleic acid reverses obesity-induced hepatic steatosis

  2019cited by this paper
• Review article: shared disease mechanisms between non‐alcoholic fatty liver disease and metabolic syndrome – translating knowledge from systems biology to the bedside

  2019cited by this paper
• Deficient Endoplasmic Reticulum-Mitochondrial Phosphatidylserine Transfer Causes Liver Disease.

  2019cited by this paper
• Defective Phosphatidylglycerol Remodeling Causes Hepatopathy, Linking Mitochondrial Dysfunction to Hepatosteatosis

  2019cited by this paper
• Implications of Mitochondrial Unfolded Protein Response and Mitokines: A Perspective on Fatty Liver Diseases

  2019cited by this paper
• Ischemia/Reperfusion Injury Revisited: An Overview of the Latest Pharmacological Strategies

  2019cited by this paper

• No citing papers are available for this paper.